Acrivon Therapeutics(ACRV)2025-03-25 21:15Financial Position - As of December 31, 2024, Acrivon Therapeutics reported a preliminary cash and cash equivalents balance of approximately $184.6 million[6] - The company expects its cash reserves to fund operations into 2027, indicating a strong financial position for ongoing projects[16] Clinical Trial Results - The interim data from the clinical trial showed a confirmed overall response rate (ORR) of 35% and a disease control rate (DCR) of 80% among 20 Oncosignature-positive endometrial cancer patients treated with ACR-368[12] - Among 38 Oncosignature-negative patients treated with ACR-368 plus ultra low dose gemcitabine, the confirmed ORR was approximately 13%, comparable to the best ORR of 17% in their last prior line of therapy[13] - ACR-368 demonstrated significant anti-tumor activity in patients with aggressive, refractory tumors, with 80% of BM+ patients showing tumor shrinkage[12] - The company is exploring the potential of ACR-368 + LDG in future studies based on the observed sensitization in BM- patients[13] Strategic Focus - The company has deprioritized ovarian and bladder cancers, reallocating resources to focus on ACR-368 in endometrial cancer and ACR-2316[14] - ACR-2316 is currently in a Phase 1 monotherapy clinical trial, initiated two quarters ahead of schedule, with encouraging dose proportionality observed[15] - The company estimates approximately 27,000 U.S. patients annually in the second-line setting for endometrial cancer, highlighting a significant market opportunity[13] Stakeholder Engagement - The company hosted a virtual corporate R&D event to present these findings and engage with stakeholders[8]